​

TuHURA Biosciences Stock (NASDAQ:HURA)

OwnershipFinancialsChart
TuHURA Biosciences by TradingView

Previous Close

$0.66

52W Range

$0.63 - $5.27

50D Avg

$1.21

200D Avg

$2.46

Market Cap

$35.67M

Avg Vol (3M)

$363.81K

Beta

0.02

Div Yield

-

HURA Company Profile

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

19

IPO Date

Feb 22, 2013

Website

HURA Performance

HURA Financial Summary

Dec 23Dec 22Dec 21
Revenue---
Operating Income$-29.76M$-9.93M$-7.25M
Net Income$-29.32M$-9.37M$-7.02M
EBITDA$-29.12M$-9.56M$-6.01M
Basic EPS$-0.12$-202.39$-0.17
Diluted EPS$-0.12$-202.39$-0.17

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
IRDOpus Genetics, Inc.
SPROSpero Therapeutics, Inc.
TVGNTevogen Bio Holdings Inc.
AGENAgenus Inc.
SEERSeer, Inc.
INOInovio Pharmaceuticals, Inc.
VTGNVistaGen Therapeutics, Inc.
CGTXCognition Therapeutics, Inc.
MCRBSeres Therapeutics, Inc.
ABOSAcumen Pharmaceuticals, Inc.